跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 8,417 条关于
“Hippo signaling pathway”
全部
8,417
临床试验
1,971
药物
92
机构
24
资讯
6,330
上个月
Insilico Medicine to Present First-in-Human Phase 1 Data for AI-Designed Pan-TEAD Inhibitor ISM6331 at ESMO 2026
去年
Inventiva Files 2024 Half-Year Report, Advancing Lanifibranor for MASH/NASH Treatment
3个月前
YAP1 Emerges as Key Driver of Small Cell Lung Cancer Relapse and Therapy Resistance
5个月前
Orion Pharma's ODM-212 Receives FDA Orphan Drug Designation for Mesothelioma Treatment
2年前
IAG933, a Novel YAP/TAZ-TEAD Inhibitor, Shows Promise in Preclinical Cancer Models
去年
Inventiva Restructures: Halves Workforce to Focus on Late-Stage MASH Drug Lanifibranor
23天前
Vivace Therapeutics Advances VT3989, First TEAD Inhibitor, Toward Pivotal Phase 3 Trial in Mesothelioma
2个月前
Epigenetic Therapy NTX-301 Activates Hippo Pathway to Overcome Treatment-Resistant AML
3个月前
XtalPi's AI-Designed Peptide Receives US Safety Certification While Pan-TEAD Inhibitor Advances to Clinical Trials
去年
Novartis' IAG933 Shows Promise in Advanced Solid Tumors with Specific Genetic Alterations
第 1 页,共 633 页
上一页
下一页